Stryker Corporation
- Branche
- Medical Devices
- Börse
- USA
- Land / Region
- USA
- Börsengang
- 1. Februar 1988
- Mitarbeiter
- 56.000
- Website
- www.stryker.com
Zusammengesetzter Bewertungsbereich · konservativ $170–$205 / fair $230–$300 / optimistisch $310–$360. Bei $336.74, Innerhalb des optimistischen Bereichs des inneren Werts · viele Erwartungen eingepreist.
Bei Veröffentlichung $316.48 (25. Mai 2026)
Daten von EODHD, dargestellt in der Berichtswährung; nur zu Informationszwecken, keine Anlageberatung.
Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, patient and caregiver safety technologies, navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke and venous thromboembolism; traditional brain and open skull based surgical procedures products; and orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products. The Orthopaedics segment provides implants for use in total joint replacements, such as hip, knee and shoulder, ankle, and trauma and extremities surgeries; and Mako Shoulder, which expands the smart robotics suite of applications. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 61 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.
Geschichte
Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan, completing its IPO on February 1, 1988. Kevin Lobo became CEO in October 2012 and also Chairman from July 2014, and the company has completed more than 60 acquisitions since he joined. In 2024 it recorded a $273 million goodwill impairment on its Spine reporting unit and divested part of its spinal implant business. In 2025 it acquired Inari Medical, entering the peripheral vascular field and creating a new Peripheral Vascular reporting unit, and in 2026 it signed and completed the acquisition of Amplitude Vascular Systems, adding IVL technology.
Branchenposition
Stryker is a global medical technology company operating through two segments, MedSurg and Neurotechnology and Orthopaedics, selling products to doctors, hospitals and other healthcare facilities in approximately 61 countries and employing about 56,000 people. In 2025 total revenue was $25.116 billion, with MedSurg and Neurotechnology at $15.647 billion (62%) and Orthopaedics at $9.469 billion (38%). Its Mako SmartRobotics platform spans 45+ countries with over 2 million robotic procedures completed, including more than 1 million Mako Total Knee cases. Named competitors include Zimmer Biomet, Medtronic, Johnson & Johnson MedTech, CONMED, Olympus, Smith+Nephew, Arthrex, STERIS, Terumo and Penumbra.
Noch keine Analysen zu dieser Aktie in Ihrer Sprache.